# A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

> **NCT00904202** · PHASE4 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 62 (actual)

## Conditions studied

- Postherpetic Neuralgia
- Diabetic Neuropathy
- Complex Regional Pain Syndrome
- Carpal Tunnel Syndrome
- HIV Neuropathy
- Idiopathic Sensory Neuropathy
- Peripheral Neuropathy

## Interventions

- **DRUG:** Placebo Capsules + Placebo Patch
- **DRUG:** Placebo capsules + Lidoderm®
- **DRUG:** Gabapentin + Placebo
- **DRUG:** Gabapentin + Lidoderm®
- **DRUG:** Gabapentin 300 mg capsules 1800 mg/day + placebo patch
- **DRUG:** Gabapentin 1800 mg/day + Lidoderm patch

## Key facts

- **NCT ID:** NCT00904202
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2003-06
- **Final completion:** —
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2024-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00904202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00904202, "A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00904202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*